The Clinical Efficacy and Safety of Dronedarone in the Combined Treatment of Paroxysmal Atrial Fibrillation Patients with Edoxaban
Objective To evaluate the clinical efficacy of dronedarone combined with edoxaban and investigate its ef-fect on the dynamic electrocardiogram (Holter),high-sensitivity C-reactive protein (hsCRP),and N-terminal pro-B-type natri-uretic peptide (NT-proBNP) levels in patients with paroxysmal atrial fibrillation undergoing anticoagulant therapy. Methods Sixty patients with paroxysmal atrial fibrillation requiring anticoagulation were randomly divided into two groups. The control group (n=30) received standard heart rate and anticoagulation management,while the treatment group (n=30) received additional dronedarone (400 mg bid) on the basis of standard therapy. Both groups were treated for 15 weeks. The frequency of atrial fibril-lation attacks,improvement in Holter indicators,and serum levels of hsCRP and NT-proBNP were compared before and after treatment. Results After treatment,the improvement rates of atrial fibrillation events were 71.5％ in the control group and 86.6％ in the treatment group,with the treatment group showing significantly better improvement (P<0.05). Both groups showed significant improvement in Holter indicators after treatment (P<0.05),with the treatment group demonstrating superior im-provements compared to the control group (P<0.05). Serum levels of NT-proBNP and hsCRP were significantly reduced in both groups after treatment (P<0.01),and the treatment group achieved further reductions compared to the control group (P<0.05). No serious adverse events were observed in either group during the study period. Conclusion On the basis of standard anticoagulation therapy,dronedarone shows significant efficacy in the treatment of paroxysmal atrial fibrillation,effectively controlling cardiac rhythm,re-ducing hsCRP and NT-proBNP levels,and decreasing the risk of cardiovascular events.
万方数据
维普
